A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults Aged 65 to 85 Years.

Authors:
Remich S; Kitchin N; Peterson J; Li P; Pride MW and 6 more

Journal:
J Infect Dis

Publication Year: 2024

DOI:
10.1093/infdis/jiad307

PMCID:
PMC10873164

PMID:
37531657

Journal Information

Full Title: J Infect Dis

Abbreviation: J Infect Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Communicable Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Potential conflicts of interest. S. R., N. K., P. L., M. W. P., L. B., A. S. A., W. C. G., K. U. J., S. P. L., and C. W. are current or former employees of Pfizer Inc and may hold stock and/or stock options. J. P. received support from Pfizer as a study investigator.: All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed."

Evidence found in paper:

"Financial support . This work was supported by Pfizer Inc. Funding to pay the Open Access publication charges for this article was provided by Pfizer Inc. Financial support"

Evidence found in paper:

"Clinical Trials Registration. ClinicalTrials.gov NCT02561195."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025